Diseases targeted by clinical practice guidelines (publication year) Number of authors, n Number of authors receiving payments (%), n Total amounts of payments, $ Mean payment values (standard deviation), $ Median payment values (interquartile range), $ Maximum payment values per author, $
Myotonic dystrophy (2020) 32 25 (78.1) 474,953 14,842 (26,378) 2,724 (313–16,592) 117,092
Prions diseases (2020) 27 22 (81.5) 774,907 28,700 (34,513) 10,320 (483–46,057) 127,784
HTLV-1 associated myelopathy (2019) 51 37 (72.6) 1,650,249 32,358 (80,067) 6,856 (0 – 33,413) 426,273
Dystonia (2018) 26 20 (76.9) 920,439 35,401 (63,483) 8,203 (936–41,711) 269,901
Spinocerebellar degeneration and multiple system atrophy (2018) 23 23 (100) 1,034,751 44,989 (48,592) 19,859 (4,675–87,867) 148,035
Epilepsy (2018) 21 18 (85.7) 1,640,303 78,110 (84,511) 43,284 (13,014–114,702) 273,311
Parkinson’s disease (2018) 19 18 (94.7) 3,048,371 160,441 (152,860) 111,640 (34,124–269,927) 616,579
Herpes simplex encephalitis (2017) 18 14 (77.8) 332,863 18,492 (22,461) 9,913 (1,043–30,705) 81,116
Dementia (2017) 62 55 (88.7) 4,490,709 72,431 (90,761) 29,718 (6,867–111,886) 332,147
Multiple sclerosis and neuromyelitis optica (2017) 39 33 (84.6) 1,645,834 42,201 (51,833) 13,345 (1,579–88,059) 203,598